- Spain CIMA (Spanish): search for “lornoxicam” (external search; text not reproduced)
External search; text not reproduced. Check the Philippine package insert in the products table.
Contraindications
- Severe kidney impairment (serum creatinine above 700 µmol/L)
- Severe hepatic impairment
- Severe heart failure
- Active or recurrent peptic ulcer or bleeding
- Thrombocytopenia
- Third trimester of pregnancy
Dosing: Adult
- Acute mild to moderate pain (Xefo Rapid tablets; arthritis regimens differ): 8 to 16 mg/day in 8 mg doses; 16 mg then 8 mg after 12 hours on day 1; maximum 16 mg/day thereafter
- Kidney or hepatic impairment: Reduce to once-daily dosing (avoid at CrCl <30, our judgment)
Dosing: Altered kidney function
Lornoxicam is an oxicam nonsteroidal anti-inflammatory drug (NSAID) metabolized by CYP2C9; its pharmacokinetics change little in kidney failure, but NSAID effects on kidney blood flow still apply. The Irish label reduces dosing to once daily in kidney impairment and contraindicates it in severe impairment, defined by serum creatinine above 700 µmol/L. It has no US FDA label.
Kidney function measure: The SmPC grades kidney impairment by serum creatinine: mild 150–300 µmol/L (1.7–3.4 mg/dL), moderate 300–700 µmol/L (3.4–7.9 mg/dL), severe above 700 µmol/L (above 7.9 mg/dL). Bands are mapped to creatinine clearance (CrCl) by judgment; we advise avoiding it below CrCl 30.
Show full dosing details
- CrCl ≥60 mL/min
- Usual (acute pain): 8 to 16 mg/day in 8 mg doses; day 1 may be 16 mg then 8 mg 12 hours later; maximum 16 mg/day after day 1 (SmPC).
- CrCl 30–59 mL/min
- Kidney impairment: reduce dosing frequency to once daily (SmPC). Use with caution; stop if kidney function worsens.
- CrCl 15–29 mL/min
- Avoid. The SmPC contraindicates only at serum creatinine above 700 µmol/L (above 7.9 mg/dL), but that threshold is outdated; NSAIDs at CrCl <30 risk acute kidney injury, hyperkalemia and fluid overload (our judgment, consistent with other EU NSAID labels).
- CrCl <15 mL/min (not on dialysis)
- Avoid (our judgment: CrCl <30). Severe impairment (serum creatinine above 700 µmol/L [above 7.9 mg/dL]) is contraindicated in the SmPC.
- Hemodialysis (intermittent)
- Avoid: contraindicated in severe kidney impairment (SmPC). NSAIDs threaten residual kidney function.
- Peritoneal dialysis
- Avoid: contraindicated in severe kidney impairment (SmPC).
- CRRT
- Avoid; NSAIDs worsen acute kidney injury.
- Dialyzable? Not stated (99% protein-bound).
- Monitoring Kidney function in surgery, heart failure, diuretic or nephrotoxic co-therapy; stop if kidney function deteriorates. Hemoglobin, creatinine and liver enzymes regularly if used beyond 3 months (SmPC 4.4).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (April 2015). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not recommended under 18 years (SmPC).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 4 mg, 8 mg
- Lyophilized powder for injection: 8 mg
Registered products in the Philippines
4 products registered with the Food and Drug Administration (FDA) Philippines list Lornoxicam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products4
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
LaxicoLornoxicam | 8 mg Film-Coated TabletWhite opaque PVC/PVDC/Alu blister packs x 10's (Box of 3 blister packs x 10 tablets) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY48461 | Nov 14, 2027 | |
MosanLornoxicam | 8 mg Lyophilized Powder for InjectionUSP Type I Amber Colored Glass Vial (as Active) + USP Type III Flint Glass Ampoule in 2 mL (as Diluent) in a box | Rx | Gufic Biosciences Ltd.India | SRS Life Sciences Inc. | DR-XY42158 | Jun 25, 2028 | |
Zornica-4Lornoxicam | 4 mg Film-Coated TabletBlister Pack x 10's (Box of 30's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DR-XY44141 | Jan 17, 2030 | |
Zornica-8Lornoxicam | 8 mg Film - Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DR-XY44243 | Feb 24, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Other NSAIDs, corticosteroids, SSRIs, antiplatelets | Avoid | More gastrointestinal bleeding. | Avoid other NSAIDs; caution with the rest. |
| Warfarin and other anticoagulants; heparin with neuraxial anesthesia | Adjust or monitor | More bleeding; spinal or epidural hematoma. | Monitor INR; caution with neuraxial procedures. |
| ACE inhibitors, ARBs, diuretics, beta-blockers | Adjust or monitor | Less blood-pressure effect; kidney injury and hyperkalemia. | Monitor blood pressure, kidney function and potassium. |
| Methotrexate, lithium, cyclosporine, tacrolimus, digoxin | Adjust or monitor | Higher levels or toxicity. | Monitor levels and kidney function. |
| Sulfonylureas | Adjust or monitor | More hypoglycemia. | Monitor glucose. |
| Cimetidine | Minor | Higher lornoxicam levels. | Usually no action. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Nausea, abdominal pain, dyspepsia, diarrhea, vomiting
- Headache, dizziness
Serious
- Gastrointestinal bleeding and perforation
- Thrombocytopenia, anemia
- Acute kidney failure in pre-existing kidney impairment
- Hepatotoxicity, hepatic failure
- Stevens-Johnson syndrome, toxic epidermal necrolysis
Monitoring parameters
- Kidney function in surgery, heart failure, diuretic or nephrotoxic co-therapy; stop if kidney function deteriorates. Hemoglobin, creatinine and liver enzymes regularly if used beyond 3 months (SmPC 4.4). Kidney
- Kidney function in at-risk patients
- Hemoglobin, creatinine and liver enzymes beyond 3 months
Pharmacokinetics
Key PK parameters
| Bioavailability | 90% to 100% |
|---|---|
| Time to peak | About 30 minutes (rapid tablet) |
| Half-life | 3 to 4 hours (5-hydroxy metabolite about 9 hours) |
| Half-life in kidney failure (ESKD) kidney | No significant change in kidney failure (SmPC) |
| Protein binding | 99% |
| Metabolism (CYP, transporters) | Hepatic CYP2C9 to inactive 5-hydroxylornoxicam |
| Renal excretion kidney | About 42% in urine (mainly metabolite), 50% in feces |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). Xefo Rapid 8 mg film-coated tablets SmPC (PA1547/005/004) [HPRA (Ireland) product information, April 2015; no US FDA label]. https://assets.hpra.ie/products/Human/28642/LicenseSPC_PA1547-005-004_11012017183040.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Takeda UK Limited. (2015). Xefo Rapid 8 mg film-coated tablets (lornoxicam) [Summary of product characteristics, licence PA1547/005/004; text revised April 2015]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/28642/LicenseSPC_PA1547-005-004_11012017183040.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .